Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

282.79USD
27 May 2016
Change (% chg)

$0.79 (+0.28%)
Prev Close
$282.00
Open
$282.00
Day's High
$284.25
Day's Low
$280.61
Volume
1,262,957
Avg. Vol
1,782,220
52-wk High
$420.99
52-wk Low
$242.07

BIIB.O

Chart for BIIB.O

About

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA,... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $61,945.57
Shares Outstanding(Mil.): 219.05
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 17.37 34.60 35.58
EPS (TTM): 16.28 -- --
ROI: 24.09 13.98 13.32
ROE: 33.60 15.11 14.59

Biogen, AbbVie once-monthly MS injection wins U.S. approval

The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning.

May 27 2016

UPDATE 1-Biogen, AbbVie once-monthly MS injection wins U.S. approval

May 27 The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning.

May 27 2016

BRIEF-Regenxbio and Biogen enter agreement for development of gene therapy treatments

* Regenxbio and Biogen enter exclusive license agreement for the development of gene therapy treatments for rare genetic vision disorders

May 16 2016

Biogen to spin off hemophilia drugs and focus on core neuro business

Biogen Inc plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases, the company said on Tuesday.

May 03 2016

BRIEF-Biogen announces intent to spin off its hemophilia business

* Biogen announces intent to spin off its hemophilia business

May 03 2016

BRIEF-Biogen and Abbvie receive positive opinion from the CHMP on zinbryta

* Biogen and abbvie receive positive opinion from the chmp on zinbryta(tm) (daclizumab) for treatment of multiple sclerosis

Apr 29 2016

BRIEF-Biogen appoints Michael Ehlers, executive VP of R&D

* Biogen appoints Michael Ehlers executive vice president, research and development Source text for Eikon: Further company coverage:

Apr 27 2016

BRIEF-Sobi CEO on Biogen assets: "not a time to bet the company"

* CEO, asked about interest in Biogen's hemophilia assets, says "this is not a time to bet the company on something that is at the outer limits of our capacity"

Apr 27 2016

Cost cutting helps Biogen top Wall Street estimates for quarter

Aggressive cost cutting propelled Biogen Inc to a better-than-expected first quarter profit as the biotechnology company's reorganization moves began to pay off, and its shares rose nearly 5 percent.

Apr 21 2016

UPDATE 3-Cost cutting helps Biogen top Wall Street estimates for quarter

* 1st-qtr profit $4.79/shr vs est. $4.47 (Adds company, analyst comment, share move)

Apr 21 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $113.06 +0.16
Pfizer Inc. (PFE.N) $34.61 +0.18
Novartis AG (NOVN.S) CHF79.55 -0.05
Merck & Co., Inc. (MRK.N) $56.48 +0.09
Roche Holding Ltd. (ROG.S) CHF262.00 -1.40
Roche Holding Ltd. (RO.S) CHF262.25 -1.50
Bayer AG (BAYGn.DE) €86.44 +1.11
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.91 +0.11
GlaxoSmithKline plc (GSK.L) 1,452.50p -4.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.